SpyGlass Pharma, Inc. vs Skye Bioscience, Inc. — Valuation Comparison 2026
Access all valuation models for SGP vs SKYE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →SGP scores higher with a 5.0/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing SpyGlass Pharma, Inc. (SGP) and Skye Bioscience, Inc. (SKYE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
SGP currently trades at $19.84 with a QOC of 5.0/10, while SKYE trades at $0.85 with a QOC of 3.6/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).